Is Racura Oncology Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Racura Oncology Ltd (RAC.AX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Racura Oncology Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Racura Oncology Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Racura Oncology Ltd?

Muslim investors may consider investing in Racura Oncology Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Racura Oncology Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Racura Oncology Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Racura Oncology Ltd updated?

The Shariah compliance status of Racura Oncology Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Racura Oncology Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Racura Oncology Ltd?

You can check the latest Shariah compliance status of Racura Oncology Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

RAC.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 24, 2026

Report Source: 2026 2nd Quarter Report

Racura Oncology Ltd. Stock Analysis RAC.AX

Australia Health Care Small Cap Report: Q2, 2026

Racura Oncology Ltd. is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. The firm's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterized safety profile. The firm is advancing a formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase III clinical programs in acute myeloid leukemia (AML), a Phase I a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase I a/b program in combination with the anthracycline doxorubicin, where the Company is focused on delivering both cardioprotection and enhanced anticancer activity for solid tumor patients.

Key Statistics of Racura Oncology Ltd (RAC.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD2.64AUD2.95

Today's Open

AUD2.67

Volume

270.89K

P/E Ratio (TTM)

52 Week Range

AUD1.12AUD4.90

Market Cap

484.67M

Avg. Volume

6712.00

Dividend Yield

Financial Metrics & Statements of Racura Oncology Ltd (RAC.AX)

FAQ's for Racura Oncology Ltd (RAC.AX)

According to Musaffa’s Shariah screening methodology, Racura Oncology Ltd (RAC.AX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.